Riggs, Jennifer R. team published research in Journal of Medicinal Chemistry in 2017 | 16545-68-9

HPLC of Formula: 16545-68-9, Cyclopropanol is a cyclopropane in which a hydrogen atom is replaced by a hydroxy group. It is a member of cyclopropanes and an aliphatic alcohol.
Cyclopropanol is a useful research compound. Its molecular formula is C3H6O and its molecular weight is 58.08 g/mol. The purity is usually 95%.
Cyclopropanol is a cyclic organic compound that is synthesized from sodium hydroxide solution, nitrogen atoms, and carbonyl groups. Cyclopropanol has shown inhibitory effects on inflammatory bowel disease in rats. This drug also inhibits the production of hydrogen chloride and hydrochloric acid in the stomach, which can lead to ulcers. Cyclopropanol has been found to be effective against bowel diseases such as Crohn’s disease and ulcerative colitis. This drug has been shown to have strong antioxidant properties, which may be due to its ability to reduce hydroxyl radicals., 16545-68-9.

Some low molecular weight alcohols of industrial importance are produced by the addition of water to alkenes. 16545-68-9, formula is C3H6O, Ethanol, isopropanol, 2-butanol, and tert-butanol are produced by this general method. Two implementations are employed, the direct and indirect methods. HPLC of Formula: 16545-68-9

Riggs, Jennifer R.;Nagy, Mark;Elsner, Jan;Erdman, Paul;Cashion, Dan;Robinson, Dale;Harris, Roy;Huang, Dehua;Tehrani, Lida;Deyanat-Yazdi, Gordafaried;Narla, Rama Krishna;Peng, Xiaohui;Tran, Tam;Barnes, Leo;Miller, Terra;Katz, Jason;Tang, Yang;Chen, Ming;Moghaddam, Mehran F.;Bahmanyar, Sogole;Pagarigan, Barbra;Delker, Silvia;LeBrun, Laurie;Chamberlain, Philip P.;Calabrese, Andrew;Canan, Stacie S.;Leftheris, Katerina;Zhu, Dan;Boylan, John F. research published 《 The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen》, the research content is summarized as follows. Triple neg. breast cancer (TNBC) remains a serious unmet medical need with discouragingly high relapse rates. The authors report here the synthesis and structure-activity relationship (SAR) of a novel series of 2,4,5-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines with potent activity against TNBC tumor cell lines. These compounds were discovered from a TNBC phenotypic screen and possess a unique dual inhibition profile targeting TTK (mitotic exit) and CLK2 (mRNA splicing). Design and optimization, driven with a TNBC tumor cell assay, identified potent and selective compounds with favorable in vitro and in vivo activity profiles and good iv PK properties. This cell-based driven SAR produced compounds with strong single agent in vivo efficacy in multiple TNBC xenograft models without significant body weight loss. These data supported the nomination of CC-671 (compound I) into IND-enabling studies as a single agent TNBC therapy.

HPLC of Formula: 16545-68-9, Cyclopropanol is a cyclopropane in which a hydrogen atom is replaced by a hydroxy group. It is a member of cyclopropanes and an aliphatic alcohol.
Cyclopropanol is a useful research compound. Its molecular formula is C3H6O and its molecular weight is 58.08 g/mol. The purity is usually 95%.
Cyclopropanol is a cyclic organic compound that is synthesized from sodium hydroxide solution, nitrogen atoms, and carbonyl groups. Cyclopropanol has shown inhibitory effects on inflammatory bowel disease in rats. This drug also inhibits the production of hydrogen chloride and hydrochloric acid in the stomach, which can lead to ulcers. Cyclopropanol has been found to be effective against bowel diseases such as Crohn’s disease and ulcerative colitis. This drug has been shown to have strong antioxidant properties, which may be due to its ability to reduce hydroxyl radicals., 16545-68-9.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts